Seattle Genetics Initiates Phase 2 Clinical Trial of Denintuzumab Mafodotin (SGN-CD19A) Combination Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. NAVN
9. DFTX
10. IBM

Go back to Seattle Genetics Initiates Phase 2 Clinical Trial of Denintuzumab Mafodotin (SGN-CD19A) Combination Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Seattle Genetics (SGEN) Recorded Record Sales Following Label Expansion; Needham & Company Reiterates Buy

October 30, 2015 1:12 PM EDT

Needham & Company reiterated a Buy rating and $60.00 price target on Seattle Genetics (NASDAQ: SGEN) fallowing the company's 3Q earnings results. Adcetris reported record quarterly sales of $59 million, following the company's label expansion into post transplant Hodgkin's lymphoma (HL).

Analyst Chad Messer commented, "Following... More